难治性肺炎支原体肺炎治疗的研究进展

Research Progress in the Treatment of Refractory Mycoplasma pneumoniae Pneumonia

摘要: 肺炎支原体作为儿童社区获得性肺炎的主要致病菌之一，其流行病学特征在近年呈现显著变化。自2023年秋冬以来，该病原体引发的呼吸道感染呈现异常活跃态势，临床检出率较往年同期出现明显增幅。尽管多数感染病例具有自愈倾向，但值得注意的是，临床观察显示难治性肺炎支原体肺炎及重症病例的发病率较历史数据有所上升。难治性肺炎支原体肺炎多表现为持续高热、肺部影像学进展迅速等特征，部分患儿在病程中可并发肺栓塞、胸腔积液等肺内外损害，个别患者甚至遗留支气管扩张、闭塞性支气管炎等不可逆病理改变，这对临床治疗方案选择提出了更高的精准性要求。本文通过阅读文献梳理近年来儿童难治性肺炎支原体肺炎治疗的研究现状，以期为临床决策提供参考。

Abstract: Mycoplasma pneumoniae (MP) is a predominant etiological agent for community-acquired pneumonia in pediatric populations, with its epidemiological profile undergoing notable shifts in recent years. Since the autumn and winter of 2023, the epidemiological activity of MP infections has surged significantly compared to previous years, marked by a significant increase in clinical detection rates compared to historical data from the same period. Although MP infections are often self-limiting, the proportion of severe and refractory cases has increased markedly in recent years. A subset of pediatric patients present with critical illness, prolonged disease courses, and complications involving both pulmonary and extrapulmonary systems, potentially leading to long-term sequelae such as bronchiolitis obliterans. This review synthesizes current advancements in the management of pediatric RMPP through a critical analysis of recent literature, aiming to inform evidence-based clinical decision-making.